The recent updates are very positive news especially the involvement of 2 biotech affiliates instead of the 1 mentioned in the 1/16/2019 update from the company. That update mentioned funding from other sources than the NIH unrelated to the NIH. It would be welcome news if this is the fact but I still believe that acceptance by NIH for additional funding, analysis and acceptance by that institution is a critical step neccessary for commercial acceptance in the market.
I'm not exactly sure how these processes actually work in coordination with each other but either way foward progress is being made.
Any comments are more than welcome, as always.